key: cord-1053228-pw53b837
authors: Hansen, John N.; Hine, Jason; Strout, Tania D.
title: COVID-19 and preeclampsia with severe features at 34-weeks gestation
date: 2020-06-25
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.06.052
sha: f129f8b8ad6cf36600ad336917af435855ade927
doc_id: 1053228
cord_uid: pw53b837

The evolving coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a rapid expansion of knowledge on the disease's clinical manifestations, laboratory and radiographic abnormalities, and patient trajectories. One area of particular focus is the effect that this illness may have on pregnancy and maternal-fetal disease. As of April 24, 2020, we identified 55 English language reports in the scientific literature summarizing data for 339 women and 258 fetuses and neonates. The majority of these data have focused on maternal-fetal transmission and neonatal outcomes. One systematic review and meta-analysis including the spectrum of coronaviruses [Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and COVID-19] in pregnancy noted increased rates of adverse outcomes associated with this group of infections. Here, we report the case of a COVID-19 positive woman presenting to our emergency department (ED) at 34 weeks gestation with preeclampsia. This case highlights the unique diagnostic and therapeutic challenges associated with treating patients with these concomitant diseases.

Changes that occur during pregnancy make pregnant women and their fetuses more susceptible to adverse outcomes and disease complications. 1 Research indicates that, compared to the general pregnant population, those infected with influenza are at increased risk for spontaneous abortion, preterm delivery, low birth weight, birth of a small-forgestational-age infant, and fetal demise. 2 Systematic reviews and meta-analyses conclude that pregnant women experiencing coronavirus infection are at increased risk of miscarriage, preeclampsia, cesarean birth and perinatal death. 3 Given these risks, there has been notable concern about the health and well being of pregnant patients, their fetuses, and neonates during the current COVID-19 pandemic. Data specific to the effects of COVID-19 on the pregnant patient and fetus are lacking, with the majority of research focusing on maternal-fetal transmission and neonatal outcomes. Reports on small numbers of patients suggest pregnant women infected with COVID-19 may be at risk for preterm delivery, but fetal effects seem to be limited. 4 To our knowledge, there is only one report of pre-eclampsia in a COVID-19 patient; however, details of the case are not available. 3 Here, we share the case of a patient who presented to a community emergency department (ED) at 34 weeks gestation for evaluation of respiratory symptoms in the setting of COVID-19. In the ED, her temperature was 38.9°C, heart rate 129 beats per minute (bpm), blood pressure 162/86 mmHg, respiratory rate 36 breaths per minute and oxygen saturation 98% on room air; physical exam was notable for tachypnea with clear lung sounds and suprapubic tenderness. Transesophageal echocardiogram demonstrated normal systolic function, and chest computed tomography was negative for pulmonary embolism but did demonstrate bilateral ground glass opacities typical of COVID-19 infection (Figure 2) .

Due to her COVID-19+ status and complicated course, contact between mother and baby was restricted to video conferencing and provision of breast milk for her neonate. Mother and infant were discharged on hospital day 17 after two consecutive negative COVID nasopharyngeal swabs (days 13 and 14) . Prior to discharge, she was started on hydralazine and amlodipine for chronic hypertension. Discharge plans included biweekly visiting nurses, blood pressure management, and lab draws. Presently, the patient has follow-up appointments with both obstetrics and nephrology and is doing well.

We describe a patient concomitantly diagnosed with COVID-19 and preeclampsia with severe features, ultimately delivering prematurely at 35 weeks via cesarean section. Data on the effects of COVID-19 on pregnancy are limited -this is the second case of reported preeclampsia in the setting of COVID-19 infection. 4 Due to overlapping laboratory abnormalities (transaminitis, thrombocytopenia), coexisting COVID-19 and preeclampsia can present a diagnostic dilemma. Clinicians must focus on the unique features of these disease entities (significant hypertension in preeclampsia, fever in COVID-19) to identify concurrent pathologies.

J o u r n a l P r e -p r o o f As recognized in this case, COVID-19 and preeclampsia have opposing treatment considerations. Given the potential need for emergent delivery, corticosteroids supporting fetal maturation must be considered in preeclampsia, consistent with American College of Obstetrics and Gynecology recommendations. 5 This must be weighed against the possible harmful effects of corticosteroids in patients with COVID-19. 6, 7 The degree of prematurity and anticipated postdelivery pulmonary complications must be evaluated against potential deleterious effects of corticosteroids on the maternal infectious pathology.

Pregnancy and infection

pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature

Outcomes of Coronavirus spectrum infections (SARS, MERS, COVID 1-19) during pregnancy: a systematic review and meta-analysis

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Antenatal Corticosteroid Therapy for Fetal Maturation

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection